These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35410757)

  • 1. SOHO State of the Art Updates and Next Questions: Novel Transplant and Post-Transplant Options in Acute Lymphoblastic Leukemia.
    Logan AC
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):569-574. PubMed ID: 35410757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy.
    Aldoss I; Shan H; Yang D; Clark MC; Al Malki M; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ
    Transplant Cell Ther; 2024 Aug; 30(8):788.e1-788.e9. PubMed ID: 38876428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
    Yurkiewicz I; Craig J; Muffly L
    Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
    Logan AC
    Best Pract Res Clin Haematol; 2022 Dec; 35(4):101407. PubMed ID: 36517126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOHO State of the Art Updates and Next Questions | Novel Agents and the Diminishing Role of Allogeneic Stem Cell Transplant in B-Acute Lymphoblastic Leukemia.
    Jen WY; Jabbour E; Kantarjian HM; Short NJ
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):565-572. PubMed ID: 38538495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indications for Allogeneic HCT in Adults with Acute Lymphoblastic Leukemia in First Complete Remission.
    Arslan S; Pullarkat V; Aldoss I
    Curr Treat Options Oncol; 2021 Jun; 22(7):63. PubMed ID: 34097131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment.
    Hu G; Cheng Y; Zuo Y; Chang Y; Suo P; Jia Y; Lu A; Wang Y; Jiao S; Zhang L; Sun Y; Yan C; Xu L; Zhang X; Liu K; Wang Y; Zhang L; Huang X
    Front Immunol; 2022; 13():915590. PubMed ID: 35734165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene.
    Sun YQ; Li SQ; Zhao XS; Chang YJ
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):453-464. PubMed ID: 32459519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients.
    Molina JC; Carraway HE
    Curr Treat Options Oncol; 2024 Aug; 25(8):993-1010. PubMed ID: 38916714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
    Zurko J; Ramdial J; Shadman M; Ahmed S; Szabo A; Iovino L; Tomas AA; Sauter C; Perales MA; Shah NN; Acharya UH; Jacobson C; Soiffer RJ; Wang T; Komanduri KV; Jaglowski S; Kittai AS; Denlinger N; Iqbal M; Kharfan-Dabaja MA; Ayala E; Chavez J; Jain M; Locke FL; Samara Y; Budde LE; Mei MG; Pia AD; Feldman T; Ahmed N; Jacobs R; Ghosh N; Dholaria B; Oluwole OO; Hess B; Hassan A; Kenkre VP; Reagan P; Awan F; Nieto Y; Hamadani M; Herrera AF
    Haematologica; 2023 Jan; 108(1):98-109. PubMed ID: 35833303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?
    Dhawan R; Marks DI
    Curr Hematol Malig Rep; 2017 Apr; 12(2):143-152. PubMed ID: 28215040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Short NJ; Jabbour E; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2024 Jul; 24(7):427-432. PubMed ID: 38485650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia.
    Wong ZC; Dillon LW; Hourigan CS
    Best Pract Res Clin Haematol; 2023 Jun; 36(2):101468. PubMed ID: 37353292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.